MDT

95.83

-0.32%↓

A

136.93

+0.54%↑

VEEV

220.3

-1.26%↓

HQY

91.46

-0.05%↓

PHR.US

16.42

-2.84%↓

MDT

95.83

-0.32%↓

A

136.93

+0.54%↑

VEEV

220.3

-1.26%↓

HQY

91.46

-0.05%↓

PHR.US

16.42

-2.84%↓

MDT

95.83

-0.32%↓

A

136.93

+0.54%↑

VEEV

220.3

-1.26%↓

HQY

91.46

-0.05%↓

PHR.US

16.42

-2.84%↓

MDT

95.83

-0.32%↓

A

136.93

+0.54%↑

VEEV

220.3

-1.26%↓

HQY

91.46

-0.05%↓

PHR.US

16.42

-2.84%↓

MDT

95.83

-0.32%↓

A

136.93

+0.54%↑

VEEV

220.3

-1.26%↓

HQY

91.46

-0.05%↓

PHR.US

16.42

-2.84%↓

Search

Nektar Therapeutics

Avatud

42.31 0.05

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

41.36

Max

42.65

Põhinäitajad

By Trading Economics

Sissetulek

6.1M

-36M

Müük

615K

12M

Aktsiakasum

-1.87

Kasumimarginaal

-301.289

Töötajad

61

EBITDA

6.9M

-29M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+145.29% upside

Turustatistika

By TradingEconomics

Turukapital

-270M

869M

Eelmine avamishind

42.26

Eelmine sulgemishind

42.31

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

Nektar Therapeutics Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

31. dets 2025, 22:20 UTC

Suurimad hinnamuutused turgudel

Outlook Therapeutics Shares Fall After Another FDA Rejection of Macular Degeneration Drug

31. dets 2025, 17:31 UTC

Suurimad hinnamuutused turgudel

OwlTing Climbs on Launch of $10 Million Stock-Buyback Program

31. dets 2025, 16:30 UTC

Suurimad hinnamuutused turgudel

Trump Media Gains on Plan to Distribute Digital Tokens to Shareholders

31. dets 2025, 15:19 UTC

Suurimad hinnamuutused turgudel

Axsome Shares Climb on FDA Fast‑Track for Alzheimer's Drug, Backing for Narcolepsy Filing

31. dets 2025, 15:17 UTC

Suurimad hinnamuutused turgudel

Nike Shares Rise After CEO Hill Buys $1 Million of Shares

31. dets 2025, 14:37 UTC

Suurimad hinnamuutused turgudel

Corcept Shares Fall as FDA Requires More Evidence for Hypercortisolism Drug Application

1. jaan 2026, 23:35 UTC

Market Talk

Gold Rises Amid Geopolitical Risks -- Market Talk

1. jaan 2026, 21:29 UTC

Omandamised, ülevõtmised, äriostud

BlueScope: Transaction Completed on Terms Agreed When Deal Announced on Nov 13

1. jaan 2026, 21:29 UTC

Omandamised, ülevõtmised, äriostud

BlueScope Sold Stake in JV to Tata Steel

1. jaan 2026, 21:28 UTC

Omandamised, ülevõtmised, äriostud

BlueScope Steel Says Sale of Stake in Tata BlueScope Steel Completed on Dec 31

1. jaan 2026, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

1. jaan 2026, 09:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

31. dets 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

31. dets 2025, 21:13 UTC

Omandamised, ülevõtmised, äriostud

10 People to Watch in Wealth Management in 2026 -- Barrons.com

31. dets 2025, 20:40 UTC

Market Talk

Dollar Posting Its Worst Year Since 2017 -- Market Talk

31. dets 2025, 20:22 UTC

Market Talk

Oil Posts Loss in a Year Marked By Plentiful Supply -- Market Talk

31. dets 2025, 19:50 UTC

Market Talk

U.S. Natural Gas Futures Sink on Weather Outlook -- Market Talk

31. dets 2025, 19:31 UTC

Market Talk

Precious Metals Cap Off Record Runs -- Market Talk

31. dets 2025, 18:50 UTC

Market Talk

Global Equities Roundup: Market Talk

31. dets 2025, 18:50 UTC

Market Talk

Canadian Gold Miners Enjoy a Bumper Year in 2025 -- Market Talk

31. dets 2025, 17:17 UTC

Market Talk

U.S. Natural Gas Inventories Fall Less Than Expected -- Market Talk

31. dets 2025, 17:16 UTC

Suurimad hinnamuutused turgudel

OwlTing Climbs on Launch of $10M Stock-Buyback Program

31. dets 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

31. dets 2025, 17:00 UTC

Omandamised, ülevõtmised, äriostud

Nvidia Is Getting Creative as Options to Use Its Cash Flood Narrow -- Heard on the Street -- WSJ

31. dets 2025, 15:57 UTC

Omandamised, ülevõtmised, äriostud

Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval -- Barrons.com

31. dets 2025, 15:54 UTC

Market Talk

Layoff Data Supports Dollar at End of Losing Year -- Market Talk

31. dets 2025, 15:02 UTC

Suurimad hinnamuutused turgudel

Nike Shares Rise After CEO Hill Buys $1M of Shares

31. dets 2025, 14:40 UTC

Omandamised, ülevõtmised, äriostud

Nike CEO Buys $1 Million of Stock as Insiders Bet on a Turnaround -- Barrons.com

31. dets 2025, 14:20 UTC

Market Talk

Crude Futures On Track to End the Year With Losses -- Market Talk

31. dets 2025, 13:46 UTC

Market Talk

U.S. Natural Gas Falls on Milder Weather Outlook -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Nektar Therapeutics Prognoos

Hinnasiht

By TipRanks

145.29% tõus

12 kuu keskmine prognoos

Keskmine 103.71 USD  145.29%

Kõrge 135 USD

Madal 30 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Nektar Therapeutics 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

8 ratings

6

Osta

1

Hoia

1

Müü

Tehniline skoor

By Trading Central

0.5949 / 0.7406Toetus ja vastupanu

Lühikene perspektiiv

Strong Bearish Evidence

Keskpikk perspektiiv

Strong Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

help-icon Live chat